TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Oncolytics Biotech ( (ONCY) ).
Oncolytics Biotech announced an update on its proposed registration-directed clinical trial for first-line pancreatic cancer treatment, featuring a three-arm design to evaluate the efficacy of pelareorep in combination with chemotherapy and checkpoint inhibitors. This trial aims to establish pelareorep as a pioneering immunotherapy in pancreatic cancer, potentially transforming oncology treatment and attracting strategic partnerships.
The most recent analyst rating on (ONCY) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Oncolytics Biotech stock, see the ONCY Stock Forecast page.
More about Oncolytics Biotech
Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an investigational immunotherapeutic agent. The company targets various cancers, including pancreatic and breast cancers, with its innovative approach to converting immunologically ‘cold’ tumors ‘hot’ to stimulate immune responses. Oncolytics is actively seeking strategic partnerships to enhance development and commercial impact.
Average Trading Volume: 1,155,156
Technical Sentiment Signal: Hold
Current Market Cap: $130.6M
For a thorough assessment of ONCY stock, go to TipRanks’ Stock Analysis page.